- $548.97m
- $379.27m
- 35
- 18
- 47
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.2 | ||
| Price to Tang. Book | 3.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.08% | ||
| Return on Equity | -61.5% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.26 | n/a | n/a | n/a | n/a | n/a | 42.15 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Directors
- Matthew Pauls CHM (50)
- David Lowrance CFO (53)
- Badrul Chowdhury OTH (63)
- Joseph McCracken LED (67)
- Nevan Elam IND (53)
- Richard Hawkins IND (72)
- David Ramsay IND (56)
- Ricky Sun IND (47)
- Annigje Van Es-johansson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 1st, 1995
- Public Since
- June 25th, 2001
- No. of Shareholders
- 93
- No. of Employees
- 59
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 172,633,140
- Address
- 6836 BEE CAVE ROAD, AUSTIN, 78746
- Web
- https://savarapharma.com/
- Phone
- +1 51285113796
- Contact
- Anne Erickson
- Auditors
- RSM US LLP
Upcoming Events for SVRA
Savara Inc Annual Shareholders Meeting
Q2 2025 Savara Inc Earnings Release
Similar to SVRA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Savara share price?
As of Today at 23:05 UTC, shares in Savara are trading at $3.18. This share price information is delayed by 15 minutes.
How has the Savara share price performed this year?
Shares in Savara last closed at $3.18 and the price had moved by -28.54% over the past 365 days. In terms of relative price strength the Savara share price has underperformed the S&P500 Index by -34.04% over the past year.
What are the analyst and broker recommendations for Savara?
The overall consensus recommendation for Savara is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Savara dividend yield?
Savara does not currently pay a dividend.
Does Savara pay a dividend?
Savara does not currently pay a dividend.
When does Savara next pay dividends?
Savara does not currently pay a dividend.
How do I buy Savara shares?
To buy shares in Savara you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Savara?
As of the previous close price of $3.18, shares in Savara had a market capitalisation of $548.97m.
Where are Savara shares listed?
Here are the trading details for Savara:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SVRA
What kind of share is Savara?
Based on an overall assessment of its quality, value and momentum Savara is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Savara share price forecast for 2025?
The analyst consensus target price for shares in Savara is $9.44. That is 196.86% above the last closing price of $3.18.
Analysts covering Savara currently have a consensus Earnings Per Share (EPS) forecast of -$0.53 for the next financial year.
Find out moreWhat is the trend in the Savara share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Savara. Over the past six months, its share price has underperformed the S&P500 Index by -3.69%.
As of the last closing price of $3.18, shares in Savara were trading -8.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Savara PE Ratio?
The Savara PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Savara?
Savara's management team is headed by:
- Matthew Pauls - CHM
- David Lowrance - CFO
- Badrul Chowdhury - OTH
- Joseph McCracken - LED
- Nevan Elam - IND
- Richard Hawkins - IND
- David Ramsay - IND
- Ricky Sun - IND
- Annigje Van Es-johansson - IND